Sofinnova and AWS collaborate on AI tools for life sciences

pharmafile | June 10, 2026 | News story | Research and Development |  AI, Amazon Web Services (AWS), Sofinnova 

Sofinnova Partners has announced a collaboration with Amazon Web Services (AWS) aimed at expanding the use of AI across life sciences research and company development.

The initiative will build on Sofinnova’s proprietary AI platform, Sofia, which is currently used internally to support investment decisions and scientific analysis. A new founder-facing version is planned, providing startups with access to AI-driven tools for activities including competitive landscape analysis, asset benchmarking and partnership assessment.

Under the collaboration, Sofinnova-backed companies will also gain access to AWS cloud infrastructure and technical support designed for life sciences applications.

The organisations said AI was becoming increasingly important across drug discovery and development. However, they added, adoption could be limited by infrastructure costs, fragmented systems and technical complexity.

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said AI was becoming central to how new therapies are discovered, developed and brought to patients.

According to the companies, the expanded Sofia platform will draw on more than 50 years of internal data and insights generated through Sofinnova’s investment activities. The aim is to help researchers, institutions and startups identify and evaluate opportunities more efficiently.

Dan Sheeran, Vice President and General Manager, Healthcare and Life Sciences at AWS, said the collaboration was intended to support innovation and help bring new therapies and healthcare solutions to patients more quickly.

The companies added that demand for AI tools and computing resources continues to increase across the life sciences sector, creating new opportunities to accelerate research and development